CATX

Over the past six months, Perspective Therapeutics, Inc.'s stock (CATX) declined by approximately 37.32%, with the share price at $2.81 on September 11, 2026, down from $3.59 on September 15, 2025, a 21.73% decrease. The stock's 52-week high was $6.16 and its 52-week low was $1.955. Key events include Q1 2026 earnings reporting $271 million in cash, partly due to a $164 million offering, and Q2 2026 earnings reporting an EPS of -$0.22, beating estimates, but revenue of $81.00K, missing estimates. Analyst coverage saw William Blair initiate an "Outperform" rating, reinforcing similar ratings from Wedbush and BMO Capital with an $11.00 price target, though consensus revenue estimates for FY2026 decreased. Clinical data on the [²¹²Pb]VMT-α-NET program were accepted for oral presentation at ESMO Congress 2026 and interim data were presented at ASCO 2026. Significant insider selling totaled $1,621,712 in the last three months.